The Mayo Clinic Cancer Center (MCCC) is a matrix center within the Mayo Clinic/ Mayo Medical School. The Center is made up of 351 members from 87 departments and divisions based at 3 geographical sites (Rochester, MN-MCR;Jacksonville, FL-MCF;and Phoenix/ Scottsdale, AZ-MCA). Our mission is to promote and facilitate research on the incidence, etiology, and molecular basis of cancer, and then through education and direct application of the results of such research, translate the discoveries into improved methods for cancer prevention, detection, diagnosis, prognosis, and therapy. MCCC, like Mayo Clinic in general, serves not only patients in the immediate geographical areas of MCR, MCF, and MCA, but also patients from throughout the USA and the rest of the world. MCCC has 10 research programs: Cell Biology;Developmental Therapeutics;Cancer Immunology and Immunotherapy;Gene and Virus Therapy;Women's Cancer;Gastrointestinal Cancer;Hematologic Malignancies;Neuro-oncology;Genetic Epidemiology and Risk Assessment;and Cancer Prevention and Control. Research is facilitated by: 1) 13 shared resources: Survey Research, Pharmacy, Biostatistics, Bioinformatics, Biospecimens Accessioning and Processing, Pathology Research Core, Transgenic and Knockout Core, Proteomics, Microscopy and Cell Analysis, Pharmacology, Gene and Virus Therapy, Cytogenetics, and Gene Analysis;and 2) clinical support management activities including Clinical Trials Office, PRMS, and Data and Safety Monitoring. Since the last renewal, MCCC has grown with an increase in overall peer-reviewed funding from $105.9 million to $123.6 million and an increase in NCI funding from $75.7 million to $92.7M. Of particular note is a new Ovarian SPORE and a new training grant. Furthermore, there has been successful competitive renewal of 4 other SPOREs (Lymphoma, Brain, Breast, Pancreas), as well as several multi-disciplinary and training grants. Research productivity and excellence is demonstrated by high-impact clinical and scientific publications -- several of which have led to changes in cancer care. As the MCCC moves forward, a major cross-programmatic effort will be to build on research started during the past grant period in the cancer genome with the development of new genome-guided therapy approaches.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8663460
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$5,569,750
Indirect Cost
$2,069,420
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320

Showing the most recent 10 out of 1129 publications